NasdaqGS:NVAXBiotechs
How Investors Are Reacting To Novavax (NVAX) Swinging From Losses To Profits On Vaccine Revenue
Novavax, Inc. recently reported fourth-quarter 2025 revenue of US$147.14 million and net income of US$17.53 million, alongside full-year 2025 revenue of US$1.12 billion and net income of US$440.30 million, marking a move from losses to profits versus the prior year.
The shift from a prior-year full-year net loss of US$187.50 million to net income of US$440.30 million highlights how higher vaccine-related revenues and cost discipline have materially changed Novavax’s recent financial...